drugset
drugset / Trial / NCT05565560

A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

NCT05565560 ↗

Phase 3 Active not recruiting 17 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the efficacy of apremilast in children and adolescents (ages 6 through 17 years) with moderate to severe plaque psoriasis.

Timeline

Start
2023-01-25
Primary completion
2025-11-20
Completion
2026-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 20 mg Oral
Subject Apremilast Small molecule 30 mg Oral

Indications

psoriasis